Treatment Beyond Progression With Immune Checkpoint Inhibitors-Known Unknowns

被引：29

作者：

Blumenthal, Gideon M. ^{[1
]}

Theoret, Marc R. ^{[1
]}

Pazdur, Richard ^{[1
,2
]}

机构：

[1] US FDA, Off Hematol Oncol Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20903 USA

[2] US FDA, Oncol Ctr Excellence, Silver Spring, MD 20903 USA

来源：

JAMA ONCOLOGY | 2017年 / 3卷 / 11期

关键词：

GUIDELINES; CRITERIA;

D O I：

10.1001/jamaoncol.2017.1819

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

收藏

页码：1473 / 1474

页数：2

相关论文

共 10 条

[1]

[Anonymous], 2017, EUR UROL

[2]

Approvals in 2016: the march of the checkpoint inhibitors [J].

Blumenthal, Gideon M. ;

Pazdur, Richard .

NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (03) :131-132

[3]

Brawley L, 2016, THE CANCER LETTER, V42

[4]

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[5]

Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients. [J].

Escudier, Bernardi. ;

Rini, Brian I. ;

Martini, Jean-Francois ;

Chang, Wayne Yen-Hwa ;

Breza, Jan ;

Magheli, Ahmed ;

Svedman, Christer ;

Lopatin, Margarita ;

Knezevic, Dejan ;

Goddard, Audrey D. ;

English, Patricia A. ;

Li, Rachel ;

Lin, Xun ;

Valota, Olga ;

Carteni, Giacomo ;

Staehler, Michael D. ;

Motzer, Robert J. ;

Ravaud, Alain .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[6]

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression A Subgroup Analysis of a Randomized Clinical Trial [J].

George, Saby ;

Motzer, Robert J. ;

Hammers, Hans J. ;

Redman, Bruce G. ;

Kuzel, TimothyM. ;

Tykodi, Scott S. ;

Plimack, Elizabeth R. ;

Jiang, Joel ;

Waxman, Ian M. ;

Rini, Brian I. .

JAMA ONCOLOGY, 2016, 2 (09) :1179-1186

[7]

Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials [J].

Kazandjian, Dickran ;

Keegan, Patricia ;

Suzman, Daniel L. ;

Pazdur, Richard ;

Blumenthal, Gideon M. .

SEMINARS IN ONCOLOGY, 2017, 44 (01) :3-7

[8]

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials [J].

Long, Georgina V. ;

Weber, Jeffrey S. ;

Larkin, James ;

Atkinson, Victoria ;

Grob, Jean-Jacques ;

Schadendorf, Dirk ;

Dummer, Reinhard ;

Robert, Caroline ;

Marquez-Rodas, Ivan ;

McNeil, Catriona ;

Schmidt, Henrik ;

Briscoe, Karen ;

Baurain, Jean-Francois ;

Hodi, F. Stephen ;

Wolchok, Jedd D. .

JAMA ONCOLOGY, 2017, 3 (11) :1511-1519

[9]

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics [J].

Seymour, Lesley ;

Bogaerts, Jan ;

Perrone, Andrea ;

Ford, Robert ;

Schwartz, Lawrence H. ;

Mandrekar, Sumithra ;

Lin, Nancy U. ;

Litiere, Saskia ;

Dancey, Janet ;

Chen, Alice ;

Hodi, F. Stephen ;

Therasse, Patrick ;

Hoekstra, Otto S. ;

Shankar, Lalitha K. ;

Wolchok, Jedd D. ;

Ballinger, Marcus ;

Caramella, Caroline ;

de Vries, Elisabeth G. E. .

LANCET ONCOLOGY, 2017, 18 (03) :E143-E152

[10]

Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205